|
|
- 2017
Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate CancerDOI: 10.1016/j.neo.2017.06.003 Keywords: BGN, Biglycan, CHD1, Chromodomain-helicase-DNA-binding protein 1, ERCC1, Excision repair cross-complementation, ERG, Erythroblast transformation-specific (ETS) related gene, FISH, Fluorescence in situ hybridization, FOXP1, Fork head box protein P1, Ki67LI, Ki67 labeling index, MAP3K7, Mitogen-activated protein kinase kinase kinase 7, PSA, Prostate specific antigen, PTEN, Phosphatase and tensin homolog, SLRP, Small leucine-rich proteoglycan, TGF-β, Transforming growth factor β, TMA, Tissue microarray, TMPRSS2, Trans membrane protease, serine 2 Abstract: Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its relationship to molecularly defined subsets, we analyzed BGN expression by immunohistochemistry on a tissue microarray containing 12,427 prostate cancers. Seventy-eight percent of 11,050 interpretable cancers showed BGN expression, which was considered as low intensity in 47.7% and as high intensity in 31.1% of cancers. BGN protein expression rose with increasing pathological tumor stage, Gleason grade, lymph node metastasis and early PSA recurrence (P < .0001 each). Comparison with our molecular database attached to the TMA revealed that BGN expression was linked to presence of TMPRRS2:ERG fusion and PTEN deletion (P < .0001 each). In addition, BGN was strongly linked to androgen-receptor (AR) levels (P < .0001), suggesting a hormone-depending regulation of BGN. BGN up-regulation is a frequent feature of prostate cancer that parallels tumor progression and may be useful to estimate tumor aggressiveness particularly if combined with other molecular markers
|
